Search

Background: Obstructive sleep apnoea (OSA) is the most common and clinically significant sleep breathing disorder, with a high prevalence in elderly with cardiovascular diseases . OSA is often under-recognised and under-treated in clinical practice. The aim of this study is to investigate possible differences in major cardiovascular events (MACE) incidence and Paroxysmal Atrial Fibrillation (PAF) recurrence between patients receiving Continuous positive airway pressure (CPAP) treatment versus no CPAP treatment, in a cohort of elderly OSA patients with several comorbidities and history of PAF., Methods: In this prospective observational study we enrolled 420 patients aged ≥65 years, suffering from PAF, with a first diagnosis of moderate/severe OSA and indication for CPAP-mode ventilotherapy. Patients underwent clinical-instrumental and laboratory evaluation for a mean follow-up of 22.0 months., Results: CPAP treatment added on usual pharmacological care was associated with a reduced risk of MACE (HR 0.31, p < 0.001) and recurrence of PAF (HR 0.33, p < 0.001)., Conclusion: This study supports the role of moderate/severe OSA as a risk factor for MACE and recurrent AF. CPAP treatment with optimal compliance and good tolerability, combined with usual medical care for cardiometabolic comorbidities, is associated with a lower incidence of MACE and recurrent PAF in elderly with several comorbidities., Competing Interests: Declaration of competing interest The authors declare they have no conflict of interest., (Copyright © 2024. Published by Elsevier B.V.)

Background: Heart failure (HF) with preserved ejection fraction (HFpEF) represents a major comorbidity in the elderly and is associated with cognitive impairment (CoI) and type 2 diabetes mellitus (T2DM). In this context, there is an increase in oxidative stress and platelet activation biomarkers. The aim of this study was to evaluate the effects of 6 months' treatment with SGLT2i on functional, mood-related, and cognitive aspects, assessed by performing a comprehensive geriatric assessment (CGA), and on oxidative stress and platelet activation biomarkers, in a cohort of HFpEF elderly patients with T2DM. We recruited 150 elderly outpatients (mean age 75.8 ± 7.4 years)., Results: At six-month follow-up, there was a significant improvement in MMSE ( p < 0.0001), MoCA ( p < 0.0001), GDS score ( p < 0.0001), and SPPB ( p < 0.0001). Moreover, we observed a significant reduction in Nox-2 ( p < 0.0001), 8-Isoprostane ( p < 0.0001), Sp-Selectin ( p < 0.0001), and Gp-VI ( p < 0.0001). Considering ΔMMSE as the dependent variable, ΔE/e', ΔNox-2, ΔHOMA, Δ8-Isoprostane, and ΔUricemia were associated for 59.6% with ΔMMSE. When ΔMoCA was considered as the dependent variable, ΔHOMA, ΔE/e', Δ8-Isoprostane, ΔNox-2 and ΔUricemia were associated for 59.2%. Considering ΔGDS as the dependent variable, ΔHOMA, ΔNox-2, Δ8-Isoprostane, and ΔUricemia were associated with 41.6% of ΔGDS variation. Finally, ΔHOMA was the main predictor of ΔSPPB, which was associated with 21.3% with ΔSPPB, Δ8-Isoprostane, ΔNox-2, ΔE/e', and ΔUricemia added another 24.1%., Conclusion: The use of SGLT2i in elderly patients with T2DM and HFpEF significantly contributes to improving CGA scales and biomarkers of OS and PA.